Clinical Trials Logo

Clinical Trial Summary

SpA is a chronic, debilitating inflammatory rheumatic disease that affects axial and peripheral joints, internal organs, and other tissues. Sacroiliitis is a hallmark of axial SpA. Sacroliliitis has a great effect on spine pain, function and cephalic progression of the disease . The prevalence of SpA ranged from 9 to 30 per 10,000 persons in Caucasian populations, Europe or the United States . The management of axial SpA is really challenging. The traditional disease-modifying anti-rheumatic drugs (DMARDs) were ineffective in controlling the axial disease. Biological agents such as tumor necrosis factor alpha (TNFα) inhibitor and anti-interleukin 17 have shown promising results in achieving remission or low disease activity for axial SpA . Magnetic resonance imaging (MRI) is established as the imaging method of choice for the early diagnosis and follow-up of SpA patients. Although a positive imaging detection of the axial skeleton is no longer obligatory based on the new Assessment of Spondyloarthritis International Society (ASAS) classification criteria 2010, MRI imaging still plays a crucial role, especially in the early diagnosis arm. MRI has a high sensitivity in detection of acute inflammatory processes as well as the high-resolution visualization of anatomical alterations. The lack of radiation exposure makes MRI ideal for monitoring response to treatment .Bone marrow edema (BME) not only showed high sensitivity for detection of early sacroilitis, but also its reduction was a worthy indicator for disease remission. Intra Articular (IA) injections of SIJ with corticosteroids and anesthestics are often performed for pain relief. Although this technique is relatively old, it was not used on a lrage scale in axial SpA patients. Further, its effect on disease outcome measures were not well elucidated. To the best of our knowledge there is no single study have evaluated effect of steroid and local aneshestic injection on improvement of BME . Image guidance of the SIJ injection is fundamanetal, due to the complex anatomy of the joint causing a low accuracy when performed using blind technique .


Clinical Trial Description

Study design: Randomized, double-blinded, prospective, placebo-controlled clinical trial. Aim of the work To evaluate the effectiveness of steroid and anestheisa injection on BME and disease outcome measures in SIJs of axial SpA patients . Patients and methods This study will be a prospective, single-center, randomized, blind clinical trial. It will be performed on patients following in the rheumatology and rehabilitation department in Sohag University Hospitals, Faculty of Medicine: N=60 fulfilling ASAS 2010 criteria for axial SpA, will be divided randomly into 2 groups. Group 1 the active group will receive triamcinilone 40 mg injection (Kenacort) + 4 ml of .5 % lidocaine hydrochloride (Xylocaine) under ultrasound guidance. Group 2 will receive similar amount of saline injecteed subcutaneously. Only the patient will be blinded. Particpants will be initially studied with no certain condition for medications wich will be kept unchanged during the study. MRI will be done at base line and BME will be considered as an entry criteria. SPArcc score will be berfoemed at baseline and in the follow-up at 24 weeks post-injection. Clinical out come measures including ASDAS BSADAI and BASMI will be performed at baseline and 12 and 24 weeks after SIJ injection. Inclusion criteria: - Pateint >18 years old. - Patients fulfilling ASAS criteria for SpA with a diagnosis confirmed by a rheumatologist. - Patients having BME of the SIJ on MRI . - Able to be followed-up regularly. Exclusion criteria: - Patient < 18 years old. - Malignancy, DM, Hepatitis and active infectious disorders - Spine surgery. - Ankylosed sacroiliac joint - Recent SIJ injection ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04895228
Study type Interventional
Source Sohag University
Contact maher
Phone 01143619857
Email sohier.ahmed@med.sohag.edu.eg
Status Recruiting
Phase N/A
Start date May 15, 2021
Completion date December 20, 2021

See also
  Status Clinical Trial Phase
Completed NCT03110224 - SCP® Observational Study of the Knee
Recruiting NCT03699046 - Evaluating the Effectiveness of Subchondroplasty for Treating Bone Marrow Lesions of the Knee N/A
Recruiting NCT05596591 - Focused Extracorporeal Shockwave Therapy for Knee Arthritis N/A
Completed NCT03941977 - Treatment of Bone Marrow Edema Lesions of the Knee With Percutaneous Grafting N/A
Completed NCT01348269 - Assessment of Efficacy of Zoledronic Acid in the Treatment of Bone Marrow Edema Syndrome Phase 3
Completed NCT03112200 - Subchondroplasty® Knee RCT N/A
Active, not recruiting NCT03494660 - SCP Hip Outcomes Study
Completed NCT01621893 - Evaluation of Subchondroplasty™ for Defects Associated With Bone Marrow Lesions
Terminated NCT03112122 - Study for the Treatment of the Bone Marrow Edema:Core Decompression VS Bone Marrow Concentrate (BMC) VS Bone Substitute Phase 4
Completed NCT03430219 - Subchondroplasty Procedure in Patients With Bone Marrow Lesions
Recruiting NCT03921489 - Subchondroplasty for Treatment of Bone Marrow Edema in the Foot and Ankle
Terminated NCT03829644 - Lumbar Bracing for People With Type I Modic Changes N/A
Recruiting NCT04963127 - Prospective Study of Diagnostic Accuracy of Spectral CT for the Detection of Bone Marrow Edema
Completed NCT04905394 - Clinical and Radiological Outcomes of Subchondroplasty in the Treatment of Bone Marrow Edema of the Knee N/A